Flunitrazepam, also known as Rohypnol, is a benzodiazepine drug that is used as a sedative-hypnotic. It is most commonly used for the treatment of insomnia and as a premedication for surgical procedures. Flunitrazepam has a high potential for misuse and abuse, and is classified as a Schedule IV controlled substance in the United States.
Flunitrazepam works by acting on the central nervous system to produce a calming effect. It binds to the GABA-A receptors in the brain, increasing the activity of the neurotransmitter GABA and producing a sedative effect. The drug is typically used as a short-term treatment for insomnia, and it is not recommended for regular use due to its risk of dependence and abuse.
Flunitrazepam has also been used in date rape due to its ability to cause memory loss and impair judgement. It has been banned in many countries, and its use is closely monitored in the United States.
For further reading, the following scientific journal articles may be of interest:
1. Bhatti, J, et al. “Flunitrazepam: A Review of Its Pharmacology, Clinical Effects, and Use as a Date Rape Drug.” CNS Drugs, vol. 28, no. 5, 2014, pp. 369–385., doi:10.1007/s40263-014-0145-9.
2. Martin-Facklam, M., et al. “Pharmacokinetics of Flunitrazepam and Its Major Metabolites in Human Subjects.” Clinical Pharmacology and Therapeutics, vol. 84, no. 4, 2008, pp. 447–454., doi:10.1038/clpt.2008.42.
3. O’Brien, C. P., et al. “The Pharmacology and Clinical Pharmacology of Flunitrazepam: A Review.” Clinical Pharmacology and Therapeutics, vol. 65, no. 6, 1999, pp. 621–633., doi:10.1016/s0009-9236(99)90171-2.